Last updated: 2026-09-16 09:06:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
ADMA Biologics, Inc. (ADMA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $8.66, with a market capitalisation of $2.05B and a P/E ratio of 11.41. Over the past 52 weeks, its price has ranged from $7.21 to $20.46. This page covers its latest market performance, valuation, price trends and company information.
$2.05B | |
$8.61 | |
$25.67 | |
$1.01 | |
$8.61 | |
59.00 | |
2.69M | |
11.41 | |
$20.46 | |
$7.21 | |
-- | |
-- |
ADMA Biologics, Inc. (ADMA) is trading at $8.66 in pre-market trading as of 2026-09-16 08:08:00, up 0.57% ($0.05) from the previous close of $8.61
Pre-market trading shows how investors are pricing ADMA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, ADMA Biologics, Inc. (ADMA) moved from $9.62 to $8.66, representing a decline of 9.99% ($0.96).
The stock traded between $8.55 and $9.65 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 2.51 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 10.9%
ADMA is currently trading at $8.66, placing it 10.9% of the way from its 52-week low of $7.21 to its 52-week high of $20.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 647 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of ADMA Biologics, Inc. (ADMA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.